Orchestra Biomed Holdings Stock Performance
| OBIO Stock | 5.77 0.33 6.07% |
The company holds a Beta of 2.4, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Orchestra BioMed will likely underperform. At this point, Orchestra BioMed Holdings has a negative expected return of -0.0901%. Please make sure to check Orchestra BioMed's total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Orchestra BioMed Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Orchestra BioMed Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Orchestra BioMed is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.29 | Five Day Return (11.84) | Year To Date Return (37.24) | Ten Year Return (51.67) | All Time Return (51.67) |
1 | Disposition of 6837 shares by Darren Sherman of Orchestra BioMed at 6.1 subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 6961 shares by Darren Sherman of Orchestra BioMed at 5.85 subject to Rule 16b-3 | 09/05/2024 |
3 | Disposition of 6819 shares by Darren Sherman of Orchestra BioMed at 5.65 subject to Rule 16b-3 | 09/06/2024 |
4 | Disposition of 1800 shares by Fain Eric S of Orchestra BioMed at 5.43 subject to Rule 16b-3 | 09/09/2024 |
5 | Disposition of 1800 shares by Fain Eric S of Orchestra BioMed at 5.34 subject to Rule 16b-3 | 09/10/2024 |
6 | Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 4.91 subject to Rule 16b-3 | 09/24/2024 |
7 | Acquisition by David Hochman of 2000 shares of Orchestra BioMed at 4.73 subject to Rule 16b-3 | 09/25/2024 |
8 | Travere Surges 11.6 percent Is This an Indication of Further Gains | 10/07/2024 |
9 | Orchestra BioMed to Participate in Jefferies London Healthcare Conference | 11/07/2024 |
10 | We Think Orchestra BioMed Holdings Needs To Drive Business Growth Carefully | 11/14/2024 |
11 | Pivots Trading Plans and Risk Controls - Stock Traders Daily | 11/18/2024 |
| Begin Period Cash Flow | 19.8 M |
Orchestra |
Orchestra BioMed Relative Risk vs. Return Landscape
If you would invest 623.00 in Orchestra BioMed Holdings on August 24, 2024 and sell it today you would lose (79.00) from holding Orchestra BioMed Holdings or give up 12.68% of portfolio value over 90 days. Orchestra BioMed Holdings is currently does not generate positive expected returns and assumes 4.9237% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Orchestra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orchestra BioMed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orchestra BioMed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orchestra BioMed Holdings, and traders can use it to determine the average amount a Orchestra BioMed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0183
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OBIO |
Estimated Market Risk
| 4.92 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Orchestra BioMed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orchestra BioMed by adding Orchestra BioMed to a well-diversified portfolio.
Orchestra BioMed Fundamentals Growth
Orchestra Stock prices reflect investors' perceptions of the future prospects and financial health of Orchestra BioMed, and Orchestra BioMed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orchestra Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (16.56) % | ||||
| Current Valuation | 140.68 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Price To Book | 4.45 X | ||||
| Price To Sales | 78.12 X | ||||
| Revenue | 2.76 M | ||||
| EBITDA | (51.22 M) | ||||
| Net Income | (49.12 M) | ||||
| Total Debt | 1.69 M | ||||
| Book Value Per Share | 1.22 X | ||||
| Cash Flow From Operations | (46.13 M) | ||||
| Earnings Per Share | (1.60) X | ||||
| Market Capitalization | 206.79 M | ||||
| Total Asset | 95.21 M | ||||
| Retained Earnings | (248.85 M) | ||||
| Working Capital | 77.91 M | ||||
About Orchestra BioMed Performance
By examining Orchestra BioMed's fundamental ratios, stakeholders can obtain critical insights into Orchestra BioMed's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Orchestra BioMed is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 286.51 | 179.55 | |
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (0.72) | (0.69) |
Things to note about Orchestra BioMed Holdings performance evaluation
Checking the ongoing alerts about Orchestra BioMed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orchestra BioMed Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orchestra BioMed generated a negative expected return over the last 90 days | |
| Orchestra BioMed has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily |
- Analyzing Orchestra BioMed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orchestra BioMed's stock is overvalued or undervalued compared to its peers.
- Examining Orchestra BioMed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orchestra BioMed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orchestra BioMed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orchestra BioMed's stock. These opinions can provide insight into Orchestra BioMed's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.